Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 15, 2021 (6 years ago)

VIMPAT (lacosamide)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

VIMPAT (lacosamide) Tablets, 200mg, 60-count bottle, Rx Only, Manufactured for: UCB, Inc. Smyrna, GA 30080, NDC 0131-2480-35

Affected NDC 0131-2480-35

Compare with the code on your package — it is the most precise check available.

Drug: Lacosamide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Vimpat
lacosamide
NDC 00131-2480
200 mg/1 Tablet, Film Coated
Oral
UCB, Inc. Rx · CV
Recalling firm
Cardinal Health Inc.
NDC code
0131-2480-35
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0590-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lacosamide recalls

See all
Class II · Moderate risk

Lacosamide Tablets

Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.

Ongoing Particulate / foreign matter Annora Pharma Private Limited NDC 31722-813-60 D-0626-2026
Class II · Moderate risk

Lacosamide Oral Solution

Defective Container: This recall is being initiated due to a leaking unit stored horizontally.

Ongoing Packaging defect Apotex Corp. NDC 60505-0405-4 D-0457-2025
Class II · Moderate risk

Lacosamide Tablets

CGMP Deviations

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-678-60 D-0337-2025
Class II · Moderate risk

Lacosamide Tablets

CGMP Deviations

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-679-60 D-0330-2025

Other recalls by Cardinal Health Inc.

All 2021 recalls
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025